About IntraBio
IntraBio is a Healthcare company based in Austin (United States) founded in 2015 by Mallory Factor, and was acquired by Shionogi in October 2026. It operates as a therapies for rare and neurodegenerative diseases are developed by IntraBio. IntraBio has raised $60.18 million across 3 funding rounds from investors including Shionogi. The company has 4 employees. Its chief executive is Mallory Factor. IntraBio offers products and services including IB1001. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Intrabio Limited.
Company details
IntraBio was founded in 2015 and is headquartered in Austin, United States. Focus is placed on developing small-molecule therapies in the biotechnology sector for orphan indications and neurodegenerative conditions. The lead candidate, IB1001, is designed to modulate lysosomal function and calcium channel regulation for diseases such as GM2 Gangliosidosis and Ataxia-Telangiectasia. Additionally, AQNEURSA (levacetylleucine) is provided for neurological symptoms in Niemann-Pick disease.
- Headquarters Austin, United States
- Employees 4
- Founders Mallory Factor
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website intrabio.com
- Social LinkedIn X
- Acquired by Shionogi (Oct 2026)
- Legal Name Intrabio Limited
Products & Services of IntraBio
IntraBio offers a comprehensive portfolio of products and services, including IB1001.
Orally administered modified amino acid for rare neurodegenerative diseases treatment
Funding Insights of IntraBio
IntraBio has successfully raised a total of $60.18M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $40.27 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $60.18M
- Total Rounds 3
- Last Round Series C — $40.27M
- First Round $4.91M
(Jan 2018)
All 3 funding rounds of IntraBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $40.27M | Series C | – | – | – |
| Apr 2023 | $15M | Series C | – | – | – |
| Jan 2018 | $4.91M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in IntraBio
IntraBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Shionogi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals are developed and manufactured for various diseases. | 1878 | shionogi.com | New York, United States |
Investor details for IntraBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IntraBio
6 people are tracked at IntraBio (5 in leadership, 1 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Mallory Factor | Founder & CEO | Leadership |
Elizabeth Weir Factor | Chief Administrative Officer | Leadership |
Jim Meyers | President & CEO | Leadership |
Cassandra Fields | Vice President External Affairs | Leadership |
Taylor Fields | Chief Product Development Officer | Leadership |
Mitchell A Kline M.D. | Venture Capital | Team |
Complete people profiles for IntraBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IntraBio
4 dated milestones of IntraBio across 11 years, from founding to its latest funding, stage changes and deals.
- Founded IntraBio is founded.
- Funding First funding round of $4.9M.
- Funding Latest funding round, Series C, of $40.3M.
- Exit Acquired by Shionogi.
Web traffic of IntraBio
The website of IntraBio (intrabio.com) receives about 3.8K visits a month.
- Monthly visits3.8K
▲ 50.5% vs previous month
Top companies in Neurology
10 companies that operate in the same segment as IntraBio (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intrabio
Complete news archive for IntraBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IntraBio
IntraBio was founded in 2015 and raised its 1st funding round 3 years after it was founded.
IntraBio is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Mallory Factor is the current CEO of IntraBio. They have also founded this company.
IntraBio is a funded company, having raised a total of $60.18M across 3 funding rounds to date. The company's 1st funding round was a Series B of $4.91M, raised on Jan 2018.
IntraBio has 4 employees.
IntraBio was founded in 2015 and is headquartered in Austin, United States. Focus is placed on developing small-molecule therapies in the biotechnology sector for orphan indications and neurodegenerative conditions. The lead candidate, IB1001, is designed to modulate lysosomal function and calcium channel regulation for diseases such as GM2 Gangliosidosis and Ataxia-Telangiectasia. Additionally, AQNEURSA (levacetylleucine) is provided for neurological symptoms in Niemann-Pick disease.
IntraBio offers IB1001.
IntraBio has 1 investor. Key investors include Shionogi.
IntraBio operates through Intrabio Limited.
Yes. IntraBio was acquired by Shionogi in October 2026.